Define antibody screen and antibody identification.
2. Differentiate between the importance and use of the antibody screen versus antibody identification regarding each of the following:
a. Potential blood recipient
b. Donor unit
c. Prenatal/Postpartum patients
d. Recently transfused patients with positive DAT (Direct Antiglobulin Test)
e. Neonate with positive DAT
3. State the three phases of testing used in the antibody screen or antibody identification and which type of antibody can be detected in each phase.
4. State the significance of a negative antibody screen.
5. State the significance of a positive antibody screen.
6. Explain the importance of obtaining a patient transfusion and medication history when investigating a positive antibody screen.
7. Given the type of antibody identified, determine the necessary procedure for compatibility testing to provide blood for transfusion for the patient.
8. Explain the purpose of the autocontrol and its relationship to the DAT.
9. Define dosage as it relates to antibody-antigen interactions.
10. Given specific red cell antigen expression, determine if the antigen expression is homozygous or heterozygous.
11. Explain the significance of using screening and panel cells with homozygous antigen expression when performing an antibody screen or identification.
12. Explain the “3 cell rule-in” rule with regard to antibody identification for single or multiple antibodies present.
13. Explain the “rule-outs” rule with regard to antibody identification.
14. Given antibody agglutination results for an antibody identification panel, perform the “3 cell rule-in” and all “rule-outs” to identify the antibody(ies) present.
15. State which blood group antigens are destroyed by enzyme treatment and which antibodies have enhanced expression when tested against enzyme treated reagent red blood cells.
16. Define mixed field agglutination.
17. Describe specific occasions when mixed field agglutination may be present and identified.
18. Given a patient history, current ABO/Rh type, antibody screening and (if applicable) antibody identification results, interpret the testing results.
19. Given a patient history, current ABO/Rh type, antibody screening and (if applicable) antibody identification results, select the appropriate ABO/Rh type of red cell products for transfusion.
20. Given a patient history, current ABO/Rh type, antibody screening and (if applicable) antibody identification results, select the appropriate ABO type of frozen component products for transfusion.
21. Given a patient history, current ABO/Rh type, antibody screening and current or historical antibody identification results, determine the appropriate red blood cell antigen negative blood that would be required for transfusion.
22. For patients in Objective #21, given the antigen frequency of those red blood cell antigens, calculate the number of red blood cell donor units that would need to be screened for transfusion to fulfill the order requested by the physician.
23. Given a patient’s ABO/Rh type and/or other red blood cell antigen phenotyping results, determine the most probable genotype of the patient.
24. Given a patient’s ABO/Rh type and/or other red blood cell antigen phenotyping results, determine the most probable genotype or phenotype of the patient’s parents.
25. Given a patient’s ABO/Rh type and/or other red blood cell antigen phenotyping results, determine the antibody(ies) present in the patient’s serum or plasma.
26. Given donor physical, screening and/or history results, determine if the donor would be accepted, temporarily deferred, or permanently deferred from donating blood products
